EA201600409A1 - RED ANTRAKHINON GROUP PIGMENT, METHOD FOR OBTAINING RED STRAIN PIGMENT PENICILLIUM OXALICUM VAR. ARMENIACA, PRODUCT OF THE METHOD, ITS APPLICATION, PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND / OR TREATMENT OF ONCOLOGICAL DISEASES - Google Patents
RED ANTRAKHINON GROUP PIGMENT, METHOD FOR OBTAINING RED STRAIN PIGMENT PENICILLIUM OXALICUM VAR. ARMENIACA, PRODUCT OF THE METHOD, ITS APPLICATION, PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND / OR TREATMENT OF ONCOLOGICAL DISEASESInfo
- Publication number
- EA201600409A1 EA201600409A1 EA201600409A EA201600409A EA201600409A1 EA 201600409 A1 EA201600409 A1 EA 201600409A1 EA 201600409 A EA201600409 A EA 201600409A EA 201600409 A EA201600409 A EA 201600409A EA 201600409 A1 EA201600409 A1 EA 201600409A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pigment
- red
- armeniaca
- penicillium oxalicum
- antrakhinon
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Предложен способ получения экзогенного красного пигмента, продуцируемого штаммом ЕС гриба Penicillium oxalicum var. Armeniaca, который обладает высокой ингибирующей активностью по отношению к росту опухолевых клеток и не проявляет негативных побочных эффектов на организм человека. Препарат не обладает цитотоксическим и мутагенным эффектом и не накапливается в организме. Полученный продукт с высокой противоопухолевой активностью может применяться в качестве лечебно- профилактического средства для лечения опухолевых заболеваний, таких как рак молочной железы, рак толстой кишки, рак печени, легочной карциномы, хронического лейкоза и обширной гепатоцеллюлярной карциномы.A method of obtaining exogenous red pigment produced by the EU strain of the fungus Penicillium oxalicum var. Armeniaca, which has a high inhibitory activity against the growth of tumor cells and does not show negative side effects on the human body. The drug does not have a cytotoxic and mutagenic effect and does not accumulate in the body. The resulting product with high antitumor activity can be used as a therapeutic and prophylactic agent for treating neoplastic diseases such as breast cancer, colon cancer, liver cancer, pulmonary carcinoma, chronic leukemia and extensive hepatocellular carcinoma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201600409A EA028640B1 (en) | 2016-06-22 | 2016-06-22 | Red pigment of anthraquinone group, method for producing red pigment of strain of penicillium oxalicum var. armeniaca fungus, product of the method, use thereof, pharmaceutical composition and method for prophylaxis and/or treatment of cancer diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201600409A EA028640B1 (en) | 2016-06-22 | 2016-06-22 | Red pigment of anthraquinone group, method for producing red pigment of strain of penicillium oxalicum var. armeniaca fungus, product of the method, use thereof, pharmaceutical composition and method for prophylaxis and/or treatment of cancer diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201600409A1 true EA201600409A1 (en) | 2017-11-30 |
EA028640B1 EA028640B1 (en) | 2017-12-29 |
Family
ID=60421444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201600409A EA028640B1 (en) | 2016-06-22 | 2016-06-22 | Red pigment of anthraquinone group, method for producing red pigment of strain of penicillium oxalicum var. armeniaca fungus, product of the method, use thereof, pharmaceutical composition and method for prophylaxis and/or treatment of cancer diseases |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA028640B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110922379A (en) * | 2018-12-04 | 2020-03-27 | 福州大学 | iso-Penicillium xanthone A from penicillium oxalicum and application in leukemia |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ97098A3 (en) * | 1998-03-30 | 1999-10-13 | Eduard Dr. Sardaryan | Strain of penicillium oxalicum var. armeniaca micro-organism and use thereof |
CZ289242B6 (en) * | 2000-08-10 | 2001-12-12 | Eduard Dr. Sardaryan | Preparation exhibiting prophylactic antitumor activity |
CZ302696B6 (en) * | 2009-11-27 | 2011-09-07 | G.E.S. Biomedical S. R. O. | Strain of Penicillium oxalicum var. Armeniaca microscopic fungus and process for preparing magenta |
-
2016
- 2016-06-22 EA EA201600409A patent/EA028640B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110922379A (en) * | 2018-12-04 | 2020-03-27 | 福州大学 | iso-Penicillium xanthone A from penicillium oxalicum and application in leukemia |
Also Published As
Publication number | Publication date |
---|---|
EA028640B1 (en) | 2017-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
PH12018502429A1 (en) | Antibody molecules for cancer treatment | |
WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
PH12017550063A1 (en) | Combination therapies for treating cancers | |
MX2021004639A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors. | |
WO2016025635A3 (en) | Combination therapy for treating cancer | |
WO2017176628A8 (en) | Methods for solid tumor treatment | |
WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
WO2016080810A3 (en) | Biguanide compound and use thereof | |
MX2017004661A (en) | Cortexolone 17alpha-benzoate for use in the treatment of tumours. | |
SA515370134B1 (en) | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging | |
MD20160016A2 (en) | Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same | |
MX2017015896A (en) | Anticancer agent. | |
WO2016043874A3 (en) | Combination therapy for treating cancer | |
MX2016014436A (en) | Heterocyclyl-butanamide derivatives. | |
MX359656B (en) | Oxoquinazolinyl-butanamide derivatives. | |
WO2016191675A3 (en) | Antibodies against glypican-3 and their uses in cancer diagnosis and treatment | |
PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
MX2020000135A (en) | New quinolinone compounds. | |
MX2022014792A (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same. | |
MX2018005515A (en) | 1,4-dicarbonyl-piperidyl derivatives. | |
WO2016087932A3 (en) | Macromolecular transition metal complexes for treatment of cancer and process for their preparation | |
EA201600409A1 (en) | RED ANTRAKHINON GROUP PIGMENT, METHOD FOR OBTAINING RED STRAIN PIGMENT PENICILLIUM OXALICUM VAR. ARMENIACA, PRODUCT OF THE METHOD, ITS APPLICATION, PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND / OR TREATMENT OF ONCOLOGICAL DISEASES | |
MX2019001337A (en) | Methods of treating and preventing cancer treatment side effects. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MD4A | Opposition filed against granted eurasian patent |
Effective date: 20180622 |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): TM |
|
QB4A | Registration of a licence in a contracting state | ||
NG4A | Rejection of opposition against grant of a eurasian patent | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ KG TJ |